These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 26655726)
1. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Wang X; Huang H; Young KH Aging (Albany NY); 2015 Dec; 7(12):1032-49. PubMed ID: 26655726 [TBL] [Abstract][Full Text] [Related]
2. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Ciuffreda L; Falcone I; Incani UC; Del Curatolo A; Conciatori F; Matteoni S; Vari S; Vaccaro V; Cognetti F; Milella M Adv Biol Regul; 2014 Sep; 56():66-80. PubMed ID: 25088603 [TBL] [Abstract][Full Text] [Related]
3. PI(3)king apart PTEN's role in cancer. Zhang S; Yu D Clin Cancer Res; 2010 Sep; 16(17):4325-30. PubMed ID: 20622047 [TBL] [Abstract][Full Text] [Related]
4. PTEN mutation: many birds with one stone in tumorigenesis. Liu W; Zhou Y; Reske SN; Shen C Anticancer Res; 2008; 28(6A):3613-9. PubMed ID: 19189642 [TBL] [Abstract][Full Text] [Related]
5. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840 [TBL] [Abstract][Full Text] [Related]
6. Regulation and modulation of PTEN activity. Naderali E; Khaki AA; Rad JS; Ali-Hemmati A; Rahmati M; Charoudeh HN Mol Biol Rep; 2018 Dec; 45(6):2869-2881. PubMed ID: 30145641 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of cancers with loss of PTEN function. Dillon LM; Miller TW Curr Drug Targets; 2014 Jan; 15(1):65-79. PubMed ID: 24387334 [TBL] [Abstract][Full Text] [Related]
8. The biology and clinical relevance of the PTEN tumor suppressor pathway. Sansal I; Sellers WR J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063 [TBL] [Abstract][Full Text] [Related]
9. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817 [TBL] [Abstract][Full Text] [Related]
11. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Liu JL; Mao Z; LaFortune TA; Alonso MM; Gallick GE; Fueyo J; Yung WK Cancer Res; 2007 Nov; 67(22):11054-63. PubMed ID: 18006852 [TBL] [Abstract][Full Text] [Related]
12. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071 [TBL] [Abstract][Full Text] [Related]
13. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Uner AH; Sağlam A; Han U; Hayran M; Sungur A; Ruacan S Leuk Lymphoma; 2005 Oct; 46(10):1463-70. PubMed ID: 16194892 [TBL] [Abstract][Full Text] [Related]
14. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Lau MT; Klausen C; Leung PC Oncogene; 2011 Jun; 30(24):2753-66. PubMed ID: 21297666 [TBL] [Abstract][Full Text] [Related]
15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
16. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway. Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813 [TBL] [Abstract][Full Text] [Related]
17. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Lin PY; Fosmire SP; Park SH; Park JY; Baksh S; Modiano JF; Weiss RH Mol Cancer; 2007 Feb; 6():16. PubMed ID: 17300726 [TBL] [Abstract][Full Text] [Related]
18. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Chen JH; Zhang P; Chen WD; Li DD; Wu XQ; Deng R; Jiao L; Li X; Ji J; Feng GK; Zeng YX; Jiang JW; Zhu XF Autophagy; 2015; 11(2):239-52. PubMed ID: 25701194 [TBL] [Abstract][Full Text] [Related]
19. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Hales EC; Taub JW; Matherly LH Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475 [TBL] [Abstract][Full Text] [Related]